COVALAB UK LIMITEDActive
Key figures
Like most small UK companies, COVALAB UK LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Ratios
2025Balance sheet structure
Filed accounts2020–2025
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Total assets | 198,251 | 181,260 | 171,945 | 164,880 | 162,978 |
| Total liabilities | — | — | — | — | — |
| Net assets / total equity | 153,948 | 153,340 | 143,259 | 151,912 | 146,070 |
| Average number of employees | 2 | 2 | 2 | 2 | 3 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2025The company's principal activity remains that of the custom production of antibodies and peptides and the sales of related products, along with research and development in the field of immunodiagnostic therapy.
As described in the company's latest filed accounts.
Summary: COVALAB UK LIMITED
Company
COVALAB UK LIMITED is a private limited company registered with Companies House under company number 04434065. It was incorporated on 9 May 2002. Its status is active. The registered office is in Cambridge (CB1). Its nature of business (SIC 2007) is other research and experimental development on natural sciences and engineering (72190).
Accounts
The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files micro-entity accounts. Net assets were £146,070, down 3.8% on the previous year. The company had an average of 3 employees. Figures are available for 6 financial years (2020–2025).
Control and charges
One person with significant control is registered.
Filing deadlines
The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 17 Nov 2026.